Inactive Instrument

Highlights Hutchison China MediTech Limited London S.E.

Equities

KYG4672N1198

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

EU Panel Backs Approval of Takeda’s Colorectal Cancer Drug	Apr. 26	MT
European Medicines Agency Committee Backs Approval of Takeda's Fruquintinib to Treat Colorectal Cancer	Apr. 26	MT
Hutchmed to Present New Data at US Cancer Research Conference	Apr. 05	MT
HUTCHMED Limited Highlights Data to be Presented at AACR Congress 2024	Apr. 05	CI
Hutchmed, Innovent Biologics Say Chinese Regulator Accepts Application for Endometrial Cancer Drug Combination	Apr. 02	MT
HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status	Apr. 02	CI
HUTCHMED Limited Announces Savolitinib sNDA Accepted in China for Treatment-Naive or Previously Treated Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC	Mar. 27	CI
Hutchmed (China) Initiates Phase II/III Clinical Trials for Autoimmune Disease Drug	Mar. 22	MT
Hutchmed Initiates Registration Stage of the Eslim-02 Phase Ii/Iii Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China	Mar. 21	CI
Hutchmed Returns to Profit in 2023; EPS Tops Estimate	Feb. 29	MT
EARNINGS: Hutchmed revenue surges, Craven House's loss widens	Feb. 28	AN
Hutchmed Swings to 2023 Profit as Revenue Increases	Feb. 28	MT
Hutchmed (China) Swings to Profit in FY23; Revenue Soars	Feb. 28	MT
HUTCHMED Limited Provides Revenue Guidance for the Year 2024	Feb. 28	CI
HUTCHMED Limited Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 28	CI
Hutchmed hails fruquintinib trial results for gastric cancer treatment	Feb. 07	AN
An undisclosed buyer acquired 50% stake in Hutchison Hain Organic Holdings Limited from HUTCHMED Limited.	Feb. 06	CI
Hutchmed Limited Highlights Presentation of Phase III Data on Fruquintinib in Second-Line Gastric Cancer At Asco Plenary Series Session	Feb. 06	CI
Hutchmed says Inmagene exercises option to licence drug candidates	Feb. 02	AN
Hutchmed celebrates cancer drug approval in hometown of Hong Kong	Jan. 30	AN

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Hutchison China MediTech Limited London S.E.

Equities

KYG4672N1198

Highlights

Filters